Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis.

ABSTRACT: Preexisting autoimmune disease affects between 10% and 30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in patients with MDS with and without autoimmune disease show discordant results. Using the Surveillance, Epidemiology, and End Results Medicare database, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 and 2017 and claim algorithms used to identify autoimmune disease, demographic characteristics, comorbidity scores, MDS histology, transfusion burden, treatment with hypomethylating agents, and hematopoietic stem cell transplantation. Cox regression models estimated the impact on survival, and competing-risk regression models defined the effect on leukemic transformation. We analyz

SUBMITTER: Adrianzen-Herrera D 

PROVIDER: S-EPMC10685168 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature